| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Isakoff SJ and Baselga J | Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. | 2011 | J. Clin. Oncol. | pmid:21172881 |
| Burris HA et al. | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. | 2011 | J. Clin. Oncol. | pmid:21172893 |
| Allison M | Can cancer clinical trials be fixed? | 2011 | Nat. Biotechnol. | pmid:21221090 |
| Yang H et al. | Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. | 2011 | Cytoskeleton (Hoboken) | pmid:21309084 |
| Sun X et al. | Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. | 2011 | Bioconjug. Chem. | pmid:21391620 |
| Kellogg BA et al. | Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. | 2011 | Bioconjug. Chem. | pmid:21425776 |
| Lopus M | Antibody-DM1 conjugates as cancer therapeutics. | 2011 | Cancer Lett. | pmid:21481526 |
| Edwards A et al. | Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. | 2011 | Dis Model Mech | pmid:21504911 |
| Barok M et al. | Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. | 2011 | Breast Cancer Res. | pmid:21510863 |
| Zhao RY et al. | Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. | 2011 | J. Med. Chem. | pmid:21517041 |
| Lapusan S et al. | Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. | 2012 | Invest New Drugs | pmid:21519855 |
| Olson EM et al. | Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. | 2012 | Ann. Oncol. | pmid:21531783 |
| Wu Y et al. | N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. | 2011 | Chembiochem | pmid:21681880 |
| Beck A et al. | World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. | 2011 Jul-Aug | MAbs | pmid:21691144 |
| Hinow P et al. | Modeling the effects of drug binding on the dynamic instability of microtubules. | 2011 | Phys Biol | pmid:21836336 |
| Fishkin N et al. | A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. | 2011 | Chem. Commun. (Camb.) | pmid:21874179 |
| Jia Y and Zhong JJ | Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum. | 2011 | Bioresour. Technol. | pmid:21907573 |
| Gupta M et al. | Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. | 2012 | J Clin Pharmacol | pmid:21953571 |
| Tuma RS | Enthusiasm for antibody-drug conjugates. | 2011 | J. Natl. Cancer Inst. | pmid:21972230 |
| Mathew J and Perez EA | Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. | 2011 | Curr Opin Oncol | pmid:21986845 |
| LoRusso PM et al. | Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. | 2011 | Clin. Cancer Res. | pmid:22003071 |
| Blanc V et al. | SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. | 2011 | Clin. Cancer Res. | pmid:22003072 |
| Bertholjotti I | [Antibody-drug conjugate--a new age for personalized cancer treatment]. | 2011 | Chimia (Aarau) | pmid:22026193 |
| Gurtner K et al. | Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. | 2012 | Radiother Oncol | pmid:22100655 |
| Bai RL et al. | Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. | 1990 | J. Biol. Chem. | pmid:2211617 |
| Eichner S et al. | The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. | 2012 | Angew. Chem. Int. Ed. Engl. | pmid:22135226 |
| Taft F et al. | Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. | 2012 | Chemistry | pmid:22170289 |
| Kang Q et al. | Biosynthesis of 3,5-AHBA-derived natural products. | 2012 | Nat Prod Rep | pmid:22193711 |
| Li Y et al. | Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis. | 2011 | Chem. Biol. | pmid:22195559 |
| Knobloch T et al. | Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility. | 2011 | Chembiochem | pmid:22238146 |
| Shen BQ et al. | Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. | 2012 | Nat. Biotechnol. | pmid:22267010 |
| Girish S et al. | Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. | 2012 | Cancer Chemother. Pharmacol. | pmid:22271209 |
| Segraves NL et al. | An isolable acyclic hemiacetal of ansamitocin P-3. | 2012 | Magn Reson Chem | pmid:22374862 |
| Erickson HK et al. | The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. | 2012 | Mol. Cancer Ther. | pmid:22408268 |
| Aldrich CD | Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. | 1979 | J. Natl. Cancer Inst. | pmid:224236 |
| Lu D et al. | Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. | 2012 | Curr. Drug Metab. | pmid:22475266 |
| Shen BQ et al. | Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. | 2012 | Curr. Drug Metab. | pmid:22475269 |
| Beeram M et al. | A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. | 2012 | Cancer | pmid:22648179 |
| Krop IE et al. | A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. | 2012 | J. Clin. Oncol. | pmid:22649126 |
| Thon JN et al. | High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. | 2012 | Blood | pmid:22665936 |
| Ito Y | [Progress of molecularly targeted therapy for breast cancer]. | 2012 | Rinsho Ketsueki | pmid:22687976 |
| Dixon JM et al. | HER2 testing in patients with breast cancer. | 2012 | BMJ | pmid:22689887 |
| Davis JA et al. | In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. | 2012 | Drug Metab. Dispos. | pmid:22752008 |
| Younes A et al. | Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. | 2012 | J. Clin. Oncol. | pmid:22753910 |
| Wings S et al. | A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa. | 2013 | Phytochemistry | pmid:22795602 |
| Erickson HK and Lambert JM | ADME of antibody-maytansinoid conjugates. | 2012 | AAPS J | pmid:22875610 |
| Bender BC et al. | A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. | 2012 | Cancer Chemother. Pharmacol. | pmid:22886072 |
| Beck A et al. | Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. | 2012 Nov-Dec | MAbs | pmid:22909934 |
| Matsubara Y | A Meg by any other name. | 2012 | Blood | pmid:22956528 |
| Chudasama VL et al. | Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. | 2012 | Clin. Pharmacol. Ther. | pmid:22968044 |
| Suwanborirux K et al. | Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. | 1990 | Experientia | pmid:2298279 |
| Garzone PD and Atkinson AJ | In search of physiologically based distribution volume estimates for macromolecules. | 2012 | Clin. Pharmacol. Ther. | pmid:22992670 |
| Verma S et al. | Trastuzumab emtansine for HER2-positive advanced breast cancer. | 2012 | N. Engl. J. Med. | pmid:23020162 |
| Siyu-Mao et al. | Two novel ansamitocin analogs from Actinosynnema pretiosum. | 2013 | Nat. Prod. Res. | pmid:23061718 |
| Interest in "smart bombs" explodes. | 2012 | Cancer Discov | pmid:23071018 | |
| Bander NH et al. | Antibody-drug conjugate technology development for hematologic disorders. | 2012 | Clin Adv Hematol Oncol | pmid:23072775 |
| Teicher BA and Doroshow JH | The promise of antibody-drug conjugates. | 2012 | N. Engl. J. Med. | pmid:23134386 |
| Barginear MF et al. | Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. | 2012 | Mol. Med. | pmid:23196784 |
| Pode-Shakked N et al. | The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. | 2013 | EMBO Mol Med | pmid:23239665 |
| Konecny GE | Emerging strategies for the dual inhibition of HER2-positive breast cancer. | 2013 | Curr. Opin. Obstet. Gynecol. | pmid:23241641 |
| Breakthrough breast cancer drug. Finally, some hope for women who've run out of options. | 2012 | Harv Health Lett | pmid:23243689 | |
| Gonçalves A et al. | [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. | 2012 | Bull Cancer | pmid:23247898 |
| Thudium K et al. | American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. | 2013 Jan-Feb | MAbs | pmid:23255090 |
| Cho WC and Roukos DH | Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. | 2013 | Expert Rev Anticancer Ther | pmid:23259420 |
| Damodaran S and Olson EM | Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. | 2012 | Hosp Pract (1995) | pmid:23299030 |
| Noguchi E and Shimizu C | [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]. | 2013 | Gan To Kagaku Ryoho | pmid:23306913 |
| Faião-Flores F et al. | Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. | 2013 | Tumour Biol. | pmid:23341182 |
| Ludueña RF et al. | Effect of phomopsin A on the alkylation of tubulin. | 1990 | Biochem. Pharmacol. | pmid:2337418 |
| Hurvitz SA et al. | Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2013 | J. Clin. Oncol. | pmid:23382472 |
| Boyraz B et al. | Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. | 2013 | Curr Med Res Opin | pmid:23402224 |
| Carol H et al. | The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. | 2013 | Clin. Cancer Res. | pmid:23426279 |
| Dagger F et al. | Regulatory volume decrease in Leishmania mexicana: effect of anti-microtubule drugs. | 2013 | Mem. Inst. Oswaldo Cruz | pmid:23440120 |
| Janthur WD et al. | Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. | 2012 | Int J Mol Sci | pmid:23443108 |
| Peddi PF and Hurvitz SA | Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. | 2013 | Future Oncol | pmid:23469968 |
| Chu YW and Polson A | Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. | 2013 | Future Oncol | pmid:23469971 |
| Dirix LY et al. | Trastuzumab emtansine in breast cancer. | 2013 | Expert Opin Biol Ther | pmid:23477731 |
| Traynor K | Ado-trastuzumab emtansine approved for advanced breast cancer. | 2013 | Am J Health Syst Pharm | pmid:23515502 |
| Zolot RS et al. | Antibody-drug conjugates. | 2013 | Nat Rev Drug Discov | pmid:23535930 |
| Lu D et al. | An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. | 2013 | Clin Pharmacokinet | pmid:23553425 |
| Boku N | HER2-positive gastric cancer. | 2014 | Gastric Cancer | pmid:23563986 |
| Yaqub F | T-DM1 for HER2-positive metastatic breast cancer. | 2013 | Lancet Oncol. | pmid:23580966 |
| Ballantyne A and Dhillon S | Trastuzumab emtansine: first global approval. | 2013 | Drugs | pmid:23620199 |
| Carrasco-Triguero M et al. | Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. | 2013 | Bioanalysis | pmid:23641693 |
| Dere R et al. | PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. | 2013 | Bioanalysis | pmid:23641694 |
| Sullivan AS et al. | Interaction of rhizoxin with bovine brain tubulin. | 1990 | Cancer Res. | pmid:2364385 |
| Ismaili N et al. | [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. | 2013 | Presse Med | pmid:23721860 |
| DeFrancesco L | Drug pipeline: 1Q13. | 2013 | Nat. Biotechnol. | pmid:23752422 |
| Johnson MS | The top 10 drug trends right now. | 2013 | Nurs Manage | pmid:23764906 |
| Pegram M | Treatment combinations for HER2-positive breast cancer. | 2013 | Oncology (Williston Park, N.Y.) | pmid:23781688 |
| Yamashita-Kashima Y et al. | Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. | 2013 | Oncol. Rep. | pmid:23783223 |
| Wood AC et al. | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. | 2013 | Pediatr Blood Cancer | pmid:23798344 |
| Kuo YH et al. | Antitumor agents, 112. Emarginatine B, a novel potent cytotoxic sesquiterpene pyridine alkaloid from Maytenus emarginata. | 1990 Mar-Apr | J. Nat. Prod. | pmid:2380715 |
| Gradishar WJ | Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. | 2013 | Ann. Oncol. | pmid:23827380 |
| Pan W et al. | Asm8, a specific LAL-type activator of 3-amino-5-hydroxybenzoate biosynthesis in ansamitocin production. | 2013 | Sci China Life Sci | pmid:23832249 |
| Bighin C et al. | Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. | 2013 | Future Oncol | pmid:23837759 |
| Diéras V and Bachelot T | The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. | 2014 | Target Oncol | pmid:23852665 |
| Haddish-Berhane N et al. | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. | 2013 | J Pharmacokinet Pharmacodyn | pmid:23933716 |
| Sapra P et al. | Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. | 2013 | Expert Rev Clin Pharmacol | pmid:23978126 |
| Mancuso L et al. | Bioreduction of aryl azides during mutasynthesis of new ansamitocins. | 2013 | Org. Lett. | pmid:23981134 |
| Deckert J et al. | A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. | 2013 | Blood | pmid:24002446 |